Proficio Capital Partners LLC Takes $657,000 Position in Stryker Corporation $SYK

Proficio Capital Partners LLC bought a new position in shares of Stryker Corporation (NYSE:SYK) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,086 shares of the medical technology company’s stock, valued at approximately $657,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in SYK. Brighton Jones LLC boosted its stake in shares of Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares in the last quarter. Schnieders Capital Management LLC. acquired a new position in Stryker in the second quarter valued at $205,000. Marshall Wace LLP boosted its position in shares of Stryker by 107.9% during the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after purchasing an additional 77,831 shares in the last quarter. Nebula Research & Development LLC acquired a new stake in shares of Stryker during the 2nd quarter worth approximately $219,000. Finally, HUB Investment Partners LLC bought a new stake in Stryker in the second quarter valued at $253,000. Institutional investors own 77.09% of the company’s stock.

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Director Mary Brainerd purchased additional Stryker shares on September 2, increasing her personal stake. Insider buying can signal confidence in the company’s valuation and outlook, although the purchase alone is unlikely to materially change earnings expectations. Stryker Insider Makes Bold New Move With Fresh Share Purchase
• Positive Sentiment: Stryker received FDA De Novo authorization for SportSuite Vision, its surgical application for Apple Vision Pro, and completed the first reported hip arthroscopy using the system. The technology could strengthen Stryker’s digital-surgery and orthopedic innovation offerings, though commercial adoption remains to be demonstrated. Stryker introduces FDA-authorized surgical application for Apple Vision Pro
• Positive Sentiment: Stryker agreed to acquire ZuriMED, adding the FiberLocker System and expanding its shoulder-care and rotator-cuff portfolio. The deal could broaden Stryker’s orthopedic product lineup and growth opportunities. Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio
• Neutral Sentiment: Analysts remain broadly optimistic about Stryker’s longer-term prospects even as the shares have underperformed the broader market. The company’s latest reported quarter exceeded earnings expectations, but its valuation remains relatively elevated, which can increase sensitivity to growth concerns. Is Stryker Stock Underperforming the Nasdaq?
• Negative Sentiment: The recent underperformance suggests investors may be focused more on valuation, execution, and market-wide factors than on the new product announcements. The ZuriMED transaction also introduces integration and spending risks, with financial terms and its near-term earnings contribution not specified in the available reports.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 50,000 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the sale, the director directly owned 2,251,375 shares in the company, valued at $765,692,637.50. This represents a 2.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Debra King sold 826 shares of Stryker stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. This represents a 11.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 351,267 shares of company stock valued at $118,197,701 over the last three months. Insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of research reports. BTIG Research dropped their price target on Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Stryker in a report on Friday, July 31st. Truist Financial boosted their price objective on Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a report on Friday, July 31st. Evercore set a $350.00 target price on shares of Stryker in a report on Monday, July 6th. Finally, Wolfe Research lowered Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Stock Down 1.7%

SYK stock opened at $312.10 on Thursday. The stock has a 50-day simple moving average of $329.60 and a two-hundred day simple moving average of $330.33. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $119.71 billion, a PE ratio of 32.34, a PEG ratio of 1.99 and a beta of 0.76. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $396.86.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter last year, the company posted $3.13 EPS. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities analysts predict that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s payout ratio is presently 36.48%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.